All In Biotech

Drug Trial Radar · NCT01914757

Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist

A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)

Last checked: Nov 20, 2026Latest source record: Jan 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,508 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,508

Actual

Start

Aug 2013

Primary completion

Mar 2016

Study completion Mar 2016

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 2, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and additional asthma controllers.

Conditions

  • Asthma

Interventions

  • BenralizumabBiological

    Benralizumab subcutaneously on study week 0 until study week 52 inclusive.

  • PlaceboBiological

    Placebo subcutaneously on study week 0 until study week 52 inclusive.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uLTime frame: Immediately following the first administration of study drug through Study Week 56.

Locations

214 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Andalusia, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Flagstaff, Arizona

  • Research Site

    Glendale, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Alhambra, California

  • Research Site

    Anaheim, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Garden Grove, California

  • Research Site

    Lakewood, California

  • Research Site

    North Hollywood, California

  • Research Site

    Northridge, California

  • Research Site

    Palmdale, California

  • Research Site

    Rancho Mirage, California

  • Research Site

    Redondo Beach, California

  • Research Site

    Rolling Hills Estate, California

  • Research Site

    Sacramento, California

  • Research Site

    Stockton, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Upland, California

  • Research Site

    Ventura, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Westminster, California

  • Research Site

    Woodland, California

  • Research Site

    Centennial, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Wheat Ridge, Colorado

  • Research Site

    Celebration, Florida

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Homestead, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Lehigh Acres, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Virginia Gardens, Florida

  • Research Site

    Gainesville, Georgia

Showing 40 of 214 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.